We are live on ! Find out more
SKYE icon

Skye Bioscience

42 hedge funds and large institutions have $12.1M invested in Skye Bioscience in 2025 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

244% more call options, than puts

Call options by funds: $55K | Put options by funds: $16K

1.73% less ownership

Funds ownership: 8.02%6.29% (-1.7%)

19% less funds holding

Funds holding: 5242 (-10)

33% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 9

43% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 23

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

85% less capital invested

Capital invested by funds: $78.1M → $12.1M (-$66M)

Holders
42
Holders Change
-10
Holders Change %
-19.23%
% of All Funds
0.51%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
13
Increased
6
Reduced
9
Closed
23
Calls
$55K
Puts
$16K
Net Calls
+$39K
Net Calls Change
-$2.16M

SKYE Hedge Fund Activity: Q4 2025 in Review

42 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Skye Bioscience (SKYE) for Q4 2025, worth a combined $12.1M — down 85% from $78.1M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of SKYE and 13 opened new positions — a net loss of 10 holders — while 9 trimmed existing stakes and 6 added.

The largest buyer was XTX Topco, opening a new position worth an estimated $77.5K. The largest seller was Ensign Peak Advisors, exiting entirely with an estimated $3.02M sold.

  • 42 institutional investors held Skye Bioscience (SKYE) as of Q4 2025, down from 52 in Q3 2025.
  • Funds reported $12.1M of Skye Bioscience stock for Q4 2025, down 85% quarter-over-quarter.
  • 13 funds opened new Skye Bioscience positions in Q4 2025 and 23 closed out, a net change of -10 holders.
  • The largest Skye Bioscience buyer in Q4 2025 was XTX Topco, an estimated $77.5K added.
  • The largest Skye Bioscience seller in Q4 2025 was Ensign Peak Advisors, an estimated $3.02M sold.

Based on aggregated 13F filings for Q4 2025.